Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.
Autor: | Kang, Byung Woog *, Jo, Jae-Cheol *, Kim, Shin *, Jang, Geundoo *, Lee, Sung Sook *, Sym, Sun Jin *, Ryu, Jin-Sook *, Kim, Won Seog *, Yoon, Sung Soo *, Suh, Cheolwon |
---|---|
Zdroj: | In Blood 16 November 2007 110(11):1914-1914 |
Databáze: | ScienceDirect |
Externí odkaz: |